Primer: CARsgen Therapeutics (2171 HK) - Aug 2026
CARsgen is a clinical-stage biopharmaceutical company at the forefront of CAR T-cell therapy, with a strategic focus on both hematological...
102 Views
𝛼SK or SearchENTITY
CARsgen Therapeutics (2171 HK)
CARsgen Therapeutics (2171 HK)
44
Analysis
Health Care • China
CARsgen Therapeutics is a clinical-stage biopharmaceutical company focused on discovering, researching, and developing innovative CAR T-cell therapies. The company's pipeline includes therapies for hematological malignancies, solid tumors, and autoimmune diseases, such as CT053 for multiple myeloma. It is headquartered in Shanghai, China, and was founded in 2014.
morex